The Brian Allman Diffuse Large B Cell Lymphoma (DLBCL) Novel Therapeutics Program
Photos
The Brian Allman Diffuse Large B Cell Lymphoma (DLBCL) Novel Therapeutics Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
Federal Tax I.D.: EIN 86-0818253